Pierre Fabre 
Welcome,         Profile    Billing    Logout  
 26 Products   211 Diseases  26 Products   208 Trials   9851 News 
293 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Braftovi (encorafenib) / Pfizer
2018-003954-26: CYP3A4*22 genotype-guided dosing of TKIs in cancer patients: a new way of personalized therapy Op basis van CYP3A4*22 genotype doseren van tyrosine-kinase remmers bij patiënten met kanker: een nieuwe manier van gepersonaliseerde therapie.

Not yet recruiting
4
198
Europe
Film-coated tablet, Capsule, hard, Coated tablet, Tablet, Cabozantinib/Cabometyx, Cobimetinib/Cotellic, Dabrafenib/Tafinlar, Dasatinib/Sprycel, Erlotinib/Tarceva, Everolimus/Afinitor/Votubia, Imatinib, Lapatinib/Tyverb, Nilotinib/Tasigna, Olaparib/Lynparza, Palbociclib/Ibrance, Ponatinib/Iclusig, Regorafenib/Stivarga, Ruxolitinib/Jakavi, Sunitinib/Sutent, Pazopanib/Votrient, Cabozantinib/Cometriq, Olaparib?Lynparza, Brigatinib - Alunbrig, Encorafenib - Braftovi, Osimertinib/Tagrisso
Erasmus MC Cancer Institute, Erasmus MC
Patients diagnosed with a neoplasm and treated with a tyrosine kinase inhibitor which is mainly metabolised by CYP3A4. Patienten gediagnosticeerd met een maligniteit en behandeld met een tyrosine kinase inhibitor welke voornamelijk wordt gemetaboliseerd door CYP3A4., Patients diagnosed with cancer and treated with a TKI. Patienten gediagnosticeerd met kanker en behandeld met een TKI., Diseases [C] - Cancer [C04]
 
 
NCT05203172 / 2021-004395-34: The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Recruiting
4
46
Europe, Canada, Japan, US, RoW
Binimetinib only treatment, Encorafenib only Treatment, Encorafenib & Binimetinib Treatment, Treatment of Encorafenib & Binimetinib & Ribociclib, Treatment of Encorafenib & Binimetinib & Cetuximab
Pfizer
Solid Tumors
12/26
12/26
COLUMBUS, NCT01909453 / 2013-001176-38: Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

Checkmark 5 year data from COLUMBUS trial in combination with Mektovi in patients with BRAF V600 mutant melanoma
Jul 2022 - Jul 2022: 5 year data from COLUMBUS trial in combination with Mektovi in patients with BRAF V600 mutant melanoma
Checkmark Update on OS data of COLUMBUS trial in combination with Mektovi in patients with BRAF V600 mutant melanoma at ASCO 2019 [screenshot]
May 2019 - Jun 2019: Update on OS data of COLUMBUS trial in combination with Mektovi in patients with BRAF V600 mutant melanoma at ASCO 2019 [screenshot]
Checkmark Approved in combination with Mektovi tablet for unresectable BRAF-mut melanoma
More
Completed
3
921
Europe, Canada, Japan, US, RoW
LGX818, MEK162, vemurafenib, Zelboraf, PLX4032, RO5185426
Pfizer
Melanoma
11/16
09/24
2021-000743-41: Encorafenib used with binimetinib versus placebo in BRAF mutant stage II melanoma after surgery to evaluate the efficacy and safety in preventingmelanoma recurrence Encorafenib utilizzato con binimetinib rispetto al placebo nel melanoma in stadio II con mutazione BRAF dopo l'intervento chirurgico per valutare l'efficacia e la sicurezza nella prevenzione recidiva del melanoma

Not yet recruiting
3
900
Europe
Encorafenib, binimetinib, [W0090], [W0074], Capsule, hard, Film-coated tablet, Braftovi, Mektovi
PIERRE FABRE MéDICAMENT, Pierre Fabre Médicament
Resected BRAF V600E/K stage II melanoma Melanoma asportato BRAF V600E/K stadio II, Stage II melanoma with mutation in the V600E/K gene after surgery Melanoma in stadio II con mutazione nel gene V600E/K dopo intervento chirurgico, Diseases [C] - Cancer [C04]
 
 
2021-004310-19: Encorafenib used with binimetinib versus placebo in BRAF mutant stage IIB/C melanoma after surgery to evaluate the efficacy and safety in preventing melanoma recurrence

Ongoing
3
815
Europe
Encorafenib, binimetinib, W0090, W0074, Capsule, hard, Film-coated tablet, Braftovi, Mektovi
Pierre Fabre Médicament, Pierre Fabre Médicament
Resected BRAF V600E/K stage IIB/C melanoma, Stage IIB/C melanoma with mutation in the V600E/K gene after surgery, Diseases [C] - Cancer [C04]
 
 
BREAKWATER, NCT04607421 / 2020-001288-99: A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Calendar Jan 2025 - Dec 2025: Approval for 1L BRAFV600E metastatic CRC (based on BREAKWATER trial)
Checkmark Data from the safety lead-in portion of BREAKWATER trial in BRAF V600E-mutant mCRC at ASCO-GI 2023
Jan 2023 - Jan 2023: Data from the safety lead-in portion of BREAKWATER trial in BRAF V600E-mutant mCRC at ASCO-GI 2023
Active, not recruiting
3
827
Europe, Canada, Japan, US, RoW
Encorafenib, Braftovi, PF-07263896, LGX818, ONO-7702, Cetuximab, Erbitux, Oxaliplatin, Eloxatin, Irinotecan, Campostar, Leucovorin, Wellcovorin, Fusilev, Khapzory, 5-FU, Fluorouracil, Capecitabine, Xeloda, Bevacizumab, Zirabev
Pfizer, Ono Pharmaceutical Co. Ltd, Merck KGaA, Darmstadt, Germany, Eli Lilly and Company
Neoplasms
12/25
12/26
STARBOARD, NCT04657991 / 2020-004850-31: A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Calendar Jan 2025 - Dec 2025: From STARBOARD trial in combination with Mektovi and Keytruda for for 1L metastatic melanoma
Active, not recruiting
3
256
Europe, Canada, US, RoW
Encorafenib, BRAFTOVI, Binimetinib, MEKTOVI, Pembrolizumab, KEYTRUDA
Pfizer, Merck Sharp & Dohme LLC
Melanoma
09/25
12/25
SU2C ACT3, NCT03803553: Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

Recruiting
3
400
US
FOLFIRI Protocol, FOLinic acid-Fluorouracil-IRInotecan regimen, ACTIVE SURVEILLANCE, Nivolumab Protocol, Nivolumab, Encorafenib/Binimetinib/Cetuximab Protocol, Enco/Bini/Cetux, Trastuzumab + Pertuzumab, Herceptin
Massachusetts General Hospital, Stand Up To Cancer
Metastatic Colon Cancer, Stage III Colon Cancer
12/26
12/27
COLUMBUS-AD, NCT05270044: Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

Active, not recruiting
3
815
Europe, Canada, RoW
Encorafenib and Binimetinib, Encorafenib: Braftovi / Binimetinib: Mektovi, Placebo to match Encorafenib ; Placebo to match Binimetinib
Pierre Fabre Medicament, European Organisation for Research and Treatment of Cancer - EORTC
Melanoma
03/27
05/35
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
A022004, NCT05710406: Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

Active, not recruiting
2/3
1
US
Encorafenib, Braftovi, LGX-818, Cetuximab, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar KL 140, Chimeric Monoclonal Antibody C225, Erbitux, Biospecimen Collection, Computed Tomography, CAT Scan, CT Scan, Magnetic Resonance Imaging, MRI, Patient Observation, Watchful Waiting
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC V8, Stage IIC Colon Cancer AJCC V8, Stage III Colon Cancer AJCC V8
06/34
06/34
BIG BANG, UMIN000031857: A multi-center proof-of-concept phase2 study of encorafenib + binimetinib + cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer

Active, not recruiting
2
36
Japan
Braftovi (encorafenib) - Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) - Ono Pharma, Pierre Fabre, Pfizer, Erbitux (cetuximab) - Eli Lilly, EMD Serono
National Cancer Center Hospital East
Colorectal cancer
 
 
jRCT2011200018: ONO-7702/7703-03:NO-7702/ONO-7703 Phase2 Study

Completed
2
19
Japan
Braftovi (encorafenib) - Pfizer, Mektovi (binimetinib) - Pfizer
Ono Pharmaceutical Co.,LTD
Radically unresectable BRAF V600-mutant thyroid cancer
 
 
ANCHOR-CRC, NCT03693170 / 2018-000271-32: Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer

Hourglass Jan 2021 - Dec 2021 : Pivotal data from trial in combination with Mektovi for 1LBRAF+ mCRC
Checkmark From ANCHOR-CRC trial for BRAF-mutant colorectal Cancer
Jul 2020 - Jul 2020: From ANCHOR-CRC trial for BRAF-mutant colorectal Cancer
Checkmark From ANCHOR-CRC trial in combination with Mektovi for BRAF-mutant colorectal Cancer at ESMO-GI 2020
Jul 2020 - Jul 2020: From ANCHOR-CRC trial in combination with Mektovi for BRAF-mutant colorectal Cancer at ESMO-GI 2020
Completed
2
95
Europe, Japan, US
encorafenib, Braftovi, Binimetinib, Mektovi, Cetuximab, Erbitux
Pierre Fabre Medicament, Pfizer, Merck KGaA, Darmstadt, Germany, Ono Pharmaceutical Co. Ltd
BRAF V600E-mutant Metastatic Colorectal Cancer
06/20
04/23
2020-003283-10: BEACON treatment with cetuximab every second week - cetuximab given every second week with encorafenib in prior treated patients with spred bowel cancer with a specific (BRAF) mutation. A drug trial.

Not yet recruiting
2
53
Europe
Solution for infusion, Capsule, hard, Erbitux, Braftovi
Camilla Qvortrup, Danish Cancer Society, Pirre Fabre
Pre-treated BRAFV600E metastatic colorectal adenocarcinoma., Spred bowel cancer with a specific (BRAF) mutation., Diseases [C] - Cancer [C04]
 
 
2019-004621-24: Encorafenib in combination with Binimetinib in Patients with BRAFV600E-mutant metastatic Lung Cancer

Not yet recruiting
2
105
Europe
Encorafenib, encorafenib, Binimetinib, Docetaxel, W0090, W0074, Capsule, hard, Film-coated tablet, Concentrate for solution for infusion, Braftovi, Mektovi
IFCT, IFCT, Pierre Fabre
BRAFV600E-mutant metastatic Non-small Cell Lung Cancer, Lung Cancer with BRAF V600E mutation, Diseases [C] - Cancer [C04]
 
 
2020-003395-41: Ex vivo drug sensitivity in metastatic colorectal cancer

Not yet recruiting
2
45
Europe
Alectinib, Crizotinib, Dasatinib, Everolimus, Gemcitabine, Idelalisib, Larotrectinib, Methotrexate, Palbociclib, Panobinostat, Pembrolizumab, Pertuzumab, Trastuzumab, Talazoparib, Venetoclax, Cetuximab, Encorafinib, Capsule, hard, Film-coated tablet, Tablet, Infusion, Injection, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Alecensa, Xalkori, Sprycel, Afinitor, Gemcitabine Accord, Zydelig, Vitrakvi, Methotrexat Accord, Ibrance, Farydak, Keytruda, Perjeta, Herceptin, Talzenna, Venclyxto, Erbitux, Braftovi
Oslo University Hospital, Oslo University Hospital
Metastatic Colorectal Cancer, Metastatic Colorectal Cancer, Diseases [C] - Cancer [C04]
 
 
ONO-7702, JapicCTI-205146: Multicenter, open-label, uncontrolled study of and ONO-7703 for metastatic colorectal cancer with BRAF gene mutations (/7703-02E)

Completed
2
Japan
Braftovi (encorafenib) - Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) - Ono Pharma, Pierre Fabre, Pfizer
Ono Pharmaceutical Co., Ltd.
Metastatic colorectal cancer with BRAF gene mutations
 
 
2020-005771-12: Treatment with encorafenib, binimetinib, and cetuximab prior to surgery in patients with BRAF V600E mutated/pMMR localized colorectal cancer

Not yet recruiting
2
48
Europe
Erbitux (cetuximab), Encorafenib, Binimetinib, Solution for infusion, Capsule, hard, , Erbitux (cetuximab), Braftovi (Encorafenib), additional label “intended for clinical trial”
AIO-Studien-gGmbH, Pierre Fabre Pharma GmbH, Merck KGaA
Patients with unresected BRAFV600E mutated/pMMR localized colorectal cancer, Patients with not resected, mutated/mismatch repairable colon cancer, Diseases [C] - Cancer [C04]
 
 
2022-001291-34: A study researching the effectiveness of regorafenib against advanced melanoma where standard therapy has failed.

Not yet recruiting
2
48
Europe
Braftovi, Binimetinib, Trametinib, Dabrafenib, EMEA/H/C/004580, EMEA/H/C/004579, EMEA/H/C/002643, Film-coated tablet, Capsule, Stivarga, Braftovi, Mektovi, Mekinist, Tafinlar
Universitair Ziekenhuis Brussel, Universitair Ziekenhuis Brussel
Advance pretreated melanoma, Patients with advance melanoma that have failed prior systemic treatment with immune checkpoint inhibitors., Diseases [C] - Cancer [C04]
 
 
PHAROS, NCT03915951 / 2019-000417-37: An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Calendar Sep 2020 - Dec 2025: Regulatory approval for BRAF+ metastatic NSCLC in combination with Braftovi
Calendar Sep 2020 - Dec 2025: Regulatory approval for BRAF+ metastatic NSCLC in combination with Mektovi
Hourglass Jul 2019 - Dec 2019 : Initial data from trial for RAS+ MSS CRC
Active, not recruiting
2
98
Europe, US, RoW
encorafenib, binimetinib
Pfizer
Non-small Cell Lung Cancer
09/22
10/25
EBRAIN-MEL, NCT03898908 / 2018-002530-20: Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain

Completed
2
48
Europe
encorafenib, Braftovi, binimetinib, Mektovi, Whole brain radiation therapy, Radiosurgery/stereotactic radiosurgery
Grupo Español Multidisciplinar de Melanoma, Pierre Fabre Medicament, MFAR
Metastatic Melanoma, Brain Metastases
10/22
07/23
2021-000828-35: Pre-surgical treatment evaluating the combination of Encorafenib and Cetuximab for patient with localised colon cancer presenting the BRAF V600E mutation Traitement pré-chirurgical évaluant l'association d'Encorafenib et de Cetuximab pour les patients atteints d'un cancer du côlon localisé présentant la mutation BRAF V600E.

Not yet recruiting
2
30
Europe
Solution for injection, Capsule, Erbitux, braftovi
Fédération Francophone de Cancérologie Digestive, PIERRE FABRE, Merck Serono S.A.S.
Adenocarcinoma of the colon or of the upper rectum (supra-peritoneal) considered operable and histologically confirmed, localised, mutated BRAF V600E, Colon or upper rectum cancer considered operable and presenting a mutation called BRAFV600E, Diseases [C] - Cancer [C04]
 
 
GMMG-BIRMA, NCT02834364: BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)

Completed
2
12
Europe
Encorafenib, LGX818, Binimetinib, MEK162
University of Heidelberg Medical Center, Array BioPharma, German Cancer Research Center, Coordinating Centre for Clinical Trials Heidelberg, University Hospital Heidelberg
Relapsed or Refractory Multiple Myeloma, Patients With BRAFV600 E or BRAFV600K Mutation
03/23
03/23
LOGIC-2, NCT02159066 / 2013-004552-38: LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Checkmark From LOGIC-2 trial for advanced BRAF V600 melanoma at ECC 2015
Sep 2015 - Sep 2015: From LOGIC-2 trial for advanced BRAF V600 melanoma at ECC 2015
Checkmark Clinical activity and tolerability data from LOGIC-2 trial of binimetinib, encorafenib with a third agent (LEE011, BKM120, BFJ398 or INC280) combination for BRAF melanoma at ECC 2015
Sep 2015 - Sep 2015: Clinical activity and tolerability data from LOGIC-2 trial of binimetinib, encorafenib with a third agent (LEE011, BKM120, BFJ398 or INC280) combination for BRAF melanoma at ECC 2015
Completed
2
158
Europe, Canada, US, RoW
LGX818, MEK162, LEE011, BGJ398, BKM120, INC280
Pfizer
Melanoma
01/23
01/23
2021-003640-24: Phase 2 Study of Encorafenib and Binimetinib Plus Pembrolizumab inParticipants With BRAF V600E/K Mutation-Positive Melanoma Who Progressed Duringor After Prior Treatment with Anti−PD-1 Therapy

Ongoing
2
150
Europe
Encorafenib, Binimetinib, Pembrolizumab, Nivolumab, Ipilimumab, PF-07263896, PF-06811462, Capsule, hard, Tablet, Concentrate for solution for infusion, BRAFTOVI®, MEKTOVI®, KEYTRUDA®, OPDIVO, Yervoy
Pfizer Inc., Pfizer Inc., 235 East 42nd Street, New York, NY 10017
metastatic or unresectable locally advanced BRAF V600E/K mutation-positive melanoma, BRAF V600E/K Mutation-Positive Melanoma, Diseases [C] - Cancer [C04]
 
 
2014-004597-42: LGX818 in combination with MEK162 in refractory or relapsed multiple myeloma patients with BRAFV600E or BRAFV600K Mutation

Not yet recruiting
2
15
Europe
encorafenib, binimetinib, LGX818, MEK162, Capsule, hard, Film-coated tablet, Mektovi
Universität Heidelberg vertreten durch die kaufmännische Direktorin, Array BioPharma
Relapsed or refractory Multiple Myeloma, Relapsed or refractory Multiple Myeloma, Diseases [C] - Cancer [C04]
 
 
PREMIUM, NCT05097378: Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma

Not yet recruiting
2
45
Europe
Encorafenib + Binimetinib, Braftovi + Mektovi, Standard Adjuvant Treatment
CCTU- Cancer Theme, Pierre Fabre Medicament
Melanoma, Cancer
09/23
01/24
EBIN, NCT03235245 / 2017-002887-42: Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

Active, not recruiting
2
271
Europe
Nivolumab + Ipilimumab, Encorafenib + Binimetinib
European Organisation for Research and Treatment of Cancer - EORTC
Unresectable Stage III Melanoma, Stage IV Melanoma
10/23
01/27
NCT04390243: Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

Terminated
2
6
US
Binimetinib, ARRY-162, ARRY-438162, MEK162, Mektovi, Encorafenib, Braftovi, LGX 818, LGX-818, LGX818
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
11/23
11/23
ENCO-BRAF, NCT04526782 / 2019-004621-24: ENCOrafenib With Binimetinib in bRAF NSCLC

Hourglass Jul 2022 - Dec 2022 : Pivotal data readout from ENCO-BRAF trial in combination with Mektovi for NSCLC
Active, not recruiting
2
119
Europe
Encorafenib 75 MG, Binimetinib 15 MG
Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre
Non Small Cell Lung Cancer, BRAF V600E
06/25
03/26
BEAVER, NCT03839342: Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations

Active, not recruiting
2
26
Canada
Binimetinib, Encorafenib
University Health Network, Toronto
Solid Tumor
12/25
12/25
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

Completed
2
107
RoW
Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan
Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany
BRAF V600E, Metastatic Colorectal Cancer
12/23
12/24
CEBBRA, NCT06207656: Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer

Recruiting
2
70
Europe
EBC
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Merck, S.L., Spain, Pierre Fabre Ibérica, S.A.
Colorectal Cancer
04/29
04/29
NCT04324112: Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

Recruiting
2
45
US
binimetinib, Encorafenib
National Cancer Institute (NCI)
Hairy Cell Leukemia
04/28
07/28
BRAVE, NCT06411600: Combination Therapy for BRAF-V600E Metastatic CRCm

Recruiting
2
94
Europe
Encorafenib, Cetuximab, Bevacizumab
Vall d'Hebron Institute of Oncology
Metastatic Colorectal Cancer
05/27
05/29
SECOMBIT, NCT02631447 / 2014-004842-92: Sequential Combo Immuno and Target Therapy () Study

Completed
2
251
Europe
LGX818, Combo target, IMP3, MEK162, IMP4, Nivolumab, Combo Immuno, IMP1, Ipilimumab, IMP2
Fondazione Melanoma Onlus, Clinical Research Technology S.r.l.
Metastatic Melanoma
05/24
05/24
MEMBRAINS, NCT03563729 / 2018-000875-34: Melanoma Metastasized to the Brain and Steroids

Recruiting
2
80
Europe
Pembrolizumab Injection [Keytruda], Ipilimumab Injection [Yervoy], Nivolumab Injection [Opdivo], Encorafenib, Binimetinib, Dabrafenib, Trametinib
Inge Marie Svane
Malignant Melanoma
06/24
06/28
ECLYPse, NCT06640166: Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.

Recruiting
2
25
Europe
encorafenib + cetuximab + FOLFIRI, encorafenib, cetuximab, FOLFIRI
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Pierre Fabre Pharma GmbH
Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumor, Colorectal Adenocarcinoma, Colorectal Cancer (CRC), Colorectal Cancer, Colon Cancer, Colon Adenocarcinoma, Colon Carcinoma, Colon Neoplasm
12/25
06/26
NCT05576896: Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

Recruiting
2
43
US
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
Northwestern University, National Cancer Institute (NCI)
Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV
07/24
07/25
BRICKET, NCT06578559: Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC

Recruiting
2
16
Europe
Cetuximab, Encorafenib
Gruppo Oncologico del Nord-Ovest, Merck Sharp & Dohme LLC, Pierre Fabre Laboratories
Colorectal Cancer
08/26
04/27
NeoBRAF, NCT05510895 / 2020-005771-12: Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer

Recruiting
2
48
Europe
Binimetinib, Encorafenib, Cetuximab
AIO-Studien-gGmbH, Pierre Fabre Pharma GmbH, Merck Serono GmbH, Germany, Universitätsklinikum Hamburg-Eppendorf
Colorectal Cancer, Colon Cancer, BRAF V600E, BRAF V600 Mutation, Localized Cancer
07/24
01/25
NEORAF, NCT05706779: Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer

Recruiting
2
30
Europe
Encorafenib Oral Capsule + Cetuximab
Federation Francophone de Cancerologie Digestive, Pierre Fabre Laboratories, Merck Sharp & Dohme LLC
Colorectal Cancer, BRAF V600E Mutation Positive
08/24
08/27
S2107, NCT05308446: Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

Active, not recruiting
2
84
US
Cetuximab, C 225, C-225, C225, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Encorafenib, Braftovi, LGX 818, LGX-818, LGX818, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
02/26
02/26
CA209-73R, NCT04061980: Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

Active, not recruiting
2
24
US
Binimetinib, ARRY-162, ARRY-438162, MEK162, Mektovi, Encorafenib, Braftovi, LGX 818, LGX-818, LGX818, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
Providence Health & Services, Providence Cancer Center, Earle A. Chiles Research Institute
BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8
10/25
10/27
TRIDeNT, NCT02910700: Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Active, not recruiting
2
52
US
Binimetinib, Dabrafenib, Encorafenib, Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study, Trametinib
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
12/25
12/25
NEXUS, jRCT2031220025: NEOADJUVANT AND ADJUVANT CHEMOTHERAPY WITH ENCORAFENIB, BINIMETINIB PLUS CETUXIMAB IN PATIENTS WITH SURGICALLY RESECTABLE BRAF V600E MUTANT COLORECTAL METASTASIS ( study)

Recruiting
2
32
Japan
Braftovi (encorafenib) - Pfizer, Mektovi (binimetinib) - Pfizer, Erbitux (cetuximab) - Eli Lilly
National Cancer Center Hospital East
Patients with surgically resectable BRAF V600E mutant colorectal metastasis
 
 
NCT04221438: Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

Terminated
2
3
US
Binimetinib, NSC 788187, ARRY-438162, MEK162, Mektovi, Conventional Surgery, Encorafenib, ONO-7702, LGX818, Fluorothymidine F-18, 18F-FLT, 3'-deoxy-3'- 18F fluorothymidine, FLT
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma
06/24
01/25
BECOME-MB, NCT04074096 / 2021-006331-26: Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis

Active, not recruiting
2
10
Europe
Stereotaxic radiosurgery (SRS), Binimetinib Oral Tablet, Mektovi, Encorafenib Oral Capsule, Braftovi, Pembrolizumab, Keytruda
UNICANCER, European Association of Dermato Oncology, Pierre Fabre Medicament, Merck Sharp & Dohme LLC
Malignant Melanoma, BRAF V600 Mutation, Brain Metastases
04/25
04/29
NCT05026983: Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

Recruiting
2
35
US
Binimetinib, ARRY-162, ARRY-438162, MEK162, Mektovi, Encorafenib, Braftovi, LGX 818, LGX-818, LGX818, Questionnaire Administration
M.D. Anderson Cancer Center
Clinical Stage IV Cutaneous Melanoma AJCC V8, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC V8
05/25
05/25
OCEANII, NCT05195632: Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer

Active, not recruiting
2
63
RoW
Encorafenib, PF-07263896 or W0090 (in Europe), LGX818 (in US), ONO-7702 (in Japan), Binimetinib, W0074 (in Europe), MEK162 (in US), ARRY-438162 (in US), ONO-7703 (in Japan)
Pierre Fabre Medicament
Non-Small Cell Lung Cancer
05/24
09/26
PORTSIDE, NCT05926960 / 2021-003640-24: A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma

Active, not recruiting
2
38
Europe
encorafenib, BRAFTOVI, binimetinib, MEKTOVI, pembrolizumab, KEYTRUDA®, ipilimumab, YERVOY, nivolumab, OPDIVO
Pfizer, Merck Sharp & Dohme LLC
Melanoma
11/25
11/25
ENCEFALO, NCT06887088: Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

Recruiting
2
33
Europe
Encorafenib + Binimetinib, cemiplimab+fianlimab
Grupo Español Multidisciplinar de Melanoma, Regeneron Pharmaceuticals, MFAR, Pierre Fabre Laboratories
Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases
01/28
01/28
BRAF, NCT03973918: Study of Binimetinib With Encorafenib in Adults With Recurrent V600-Mutated HGG

Terminated
2
5
US
Encorafenib, Braftovi, Binimetinib, Mektovi, Research Bloods, Circulating Tumor DNA, Tumor Tissue
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI), Pfizer
High Grade Glioma, BRAF V600E, BRAF V600K, Anaplastic Astrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Gliosarcoma, Glioblastoma
04/22
10/23
NCT05767879: (Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

Recruiting
2
28
Europe
Encorafenib + Binimetinib
Leiden University Medical Center, Pierre Fabre Laboratories
Melanoma Stage III, In-Transit Metastasis of Cutaneous Melanoma
01/26
01/26
SEAMARK, NCT05217446 / 2021-003715-26: A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

Active, not recruiting
2
107
Europe, Canada, US, RoW
Encorafenib, PF-07263896 LGX818 ONO-7702 W0090, Cetuximab, Erbitux, Pembrolizumab, Keytruda®, MK-3475
Pfizer, Merck Sharp & Dohme LLC, Merck KGaA, Darmstadt, Germany, Eli Lilly and Company
Metastatic Colorectal Cancer
03/26
03/27
MK3475-C01, NCT05304546: Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma

Not yet recruiting
2
12
NA
Pembrolizumab, Keytruda, MK3475, Encorafenib, Braftovi, Binimetinib, Mektovi
Dr. Ronnie Shapira
Malignant Melanoma, Metastatic Melanoma, Immunotherapy, BRAF V600E, Malignant Melanoma Stage IV
06/26
06/27
Strata PATH, NCT05097599: StrataPATH™ (Precision Indications for Approved Therapies)

Terminated
2
11
US
lorlatinib, encorafenib + binimetinib, talazoparib, sacituzumab govitecan, axitinib, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, enfortumab vedotin, Padcev
Strata Oncology, Merck Sharp & Dohme LLC, Pfizer, Gilead Sciences
Cancer, Advanced Solid Tumor
06/24
06/24
SWOG S2000, NCT04511013: A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Recruiting
2
112
US
Binimetinib, ARRY-162, ARRY-438162, MEK162, Mektovi, Encorafenib, Braftovi, LGX 818, LGX-818, LGX818, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
SWOG Cancer Research Network, National Cancer Institute (NCI)
Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
06/27
06/27
EVIDENT, NCT05725200 / 2020-003395-41: Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Recruiting
2
40
Europe
Alectinib, Cetuximab, Crizotinib, Dasatinib, Everolimus, Encorafenib, Gemcitabine, Idelalisib, Larotrectinib, Methotrexate, Palbociclib, Panobinostat, Pembrolizumab, Petrozumab, Trastuzumab, Talazoparib, Venetoclax
Oslo University Hospital, Oslo University Hospital
Metastatic Colorectal Cancer
12/38
12/40
2019-004819-31: First in human study assessing the safety, immunogenicity and efficacy of the cancer vaccine IN01 as second line of treatment in RAS and BRAF mutated metastatic colorectal cancer patients

Not yet recruiting
1/2
70
Europe
trametinib, encorafenib, IN01, Emulsion and suspension for emulsion for injection, Tablet, Capsule, hard, MEKINIST, BRAFTOVI
IN3BIO, IN3BIO
colorectal cancer at a metastatic stage, eligible for a second line treatment and presenting with a constitutive BRAF or RAS mutation, patients with a colorectal cancer with distant metastasis and laboratory identified BRAF or RAS constitutive tumour mutations eligible to receive a second line treatment, Diseases [C] - Cancer [C04]
 
 
CA209-7Y4, NCT04655157: Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma

Terminated
1/2
2
US
encorafenib, BRAFTOVI®, nivolumab, OPDIVO®, ipilimumab, Yervoy®, binimetinib, Mektovi, ARRY-162
Jason J. Luke, MD, Bristol-Myers Squibb
Melanoma
08/22
09/22
NCT01543698 / 2011-005875-17: A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

Checkmark Of binimetinib and encorafenib combination for BRAF melanoma at ASCO 2015
May 2015 - Jun 2015: Of binimetinib and encorafenib combination for BRAF melanoma at ASCO 2015
Checkmark Of binimetinib and encorafenib combination for BRAF melanoma at ASCO 2015
May 2015 - Jun 2015: Of binimetinib and encorafenib combination for BRAF melanoma at ASCO 2015
Checkmark ASCO 2015
More
Completed
1/2
189
Europe, Canada, US, RoW
LGX818, MEK162, LEE011
Pfizer
Solid Tumors Harboring a BRAF V600 Mutation
03/23
03/23
NCT03843775: A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Completed
1/2
17
US
Binimetinib, MEK162 or ARRY-438162, Encorafenib, LGX818
Memorial Sloan Kettering Cancer Center, Array BioPharma
Advanced BRAF Mutant Cancers
09/23
09/23
CELEBRATE, NCT04720768: Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma

Recruiting
1/2
78
RoW
Binimetinib, Encorafenib, Palbociclib
Peter MacCallum Cancer Centre, Australia
Melanoma, Metastasis
12/24
12/24
DETERMINE, NCT06194929: Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

Recruiting
1/2
33
US
Defactinib, Avutometinib, Encorafenib
University of Utah, Verastem, Inc.
Melanoma
01/28
01/30
LANDSCAPE 1011, NCT04585815 / 2020-002829-28: Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Terminated
1/2
34
Europe, US, RoW
Sasanlimab Prefilled syringe, Encorafenib, Binimetinib, Sasanlimab, Axitinib, SEA-TGT
Pfizer
Carcinoma, Non-Small-Cell Lung
05/23
10/24
HERKULES-3, NCT05039177: A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Active, not recruiting
1/2
102
US
ERAS-007, Encorafenib, Braftovi, Cetuximab, Erbitux, Palbociclib, Ibrance
Erasca, Inc.
Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
08/25
12/25
NCT04017650: Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

Active, not recruiting
1/2
38
US
Cetuximab, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Encorafenib, Braftovi, LGX 818, LGX-818, LGX818, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Progressive Disease, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
06/25
06/25
NCT05957367: A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

Recruiting
1/2
94
US
Inlexisertib, DCC-3116, Ripretinib, QINLOCK, DCC-2618
Deciphera Pharmaceuticals, LLC, Pfizer
GIST
03/27
03/29
Keynote 596, NCT02675946: CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors

Recruiting
1b
72
US, RoW
CGX1321, Pembrolizumab, Keytruda, encorafenib, Braftovi, cetuximab, Erbitux
Curegenix Inc., Merck Sharp & Dohme LLC
Solid Tumors, GI Cancer
03/23
03/23
NCT01436656: A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
1
107
Europe, Japan, US, RoW
LGX818
Pfizer
Melanoma and Metastatic Colorectal Cancer
10/12
11/22
2018-001946-32: A study of binimetinib and encorafenib in patients aged 12 to 17 with a specific type of melanoma (BRAF V600-mutant melanoma) that cannot be completely removed by surgery or that has spread to other areas in the body.

Not yet recruiting
1
18
RoW, Europe
Binimetinib, Encorafenib, MEK162, LGX818, Film-coated tablet, Capsule, hard, Mektovi 15 mg film-coated tablets, Braftovi 75 mg hard capsules
Array BioPharma Inc., ARRAY BIOPHARMA INC., Array Biopharma Inc.
Unresectable or metastatic BRAF V600-mutant melanoma, Melanoma (a type of cancer), that cannot be completely removed by surgery or that has spread to other areas of the body, Diseases [C] - Cancer [C04]
 
 
NCT03864042: Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Completed
1
56
Europe, Canada, US
losartan, dextromethorphan, caffeine, omeprazole, midazolam, rosuvastatin, bupropion immediate release (IR), encorafenib, binimetinib, modafinil
Pfizer, Pierre Fabre Laboratories
Advanced Solid Tumors, Metastatic Melanoma
07/22
05/23
NCT04759846: Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Withdrawn
1
12
Europe, RoW
Encorafenib + Binimetinib, Braftovi + Mektovi
Pierre Fabre Medicament
BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma, Hepatic Impairment
05/23
05/23
NCT03543969: Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Active, not recruiting
1
14
US
Encorafenib, BRAFTOVI, BRAF/MEK-inhibitor, Binimetinib, MEKTOVI, Nivolumab, Opdivo
H. Lee Moffitt Cancer Center and Research Institute
Melanoma (Skin), Skin Cancer, Skin Melanoma, Skin Carcinoma
12/24
12/28
NCT04800822: PF-07284892 in Participants With Advanced Solid Tumors

Terminated
1
53
US
PF-07284892, ARRY-558, lorlatinib, Lorbrena; PF-06463922, Lorviqua, binimetinib, Mektovi, PF-06811462, MEK162, cetuximab, Erbitux, encorafenib, Braftovi, PF-07263896, LGX818
Pfizer
Solid Tumor
06/24
06/24
NCT06102902: Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

Recruiting
1
30
US
BET Bromodomain Inhibitor ZEN-3694, BETi ZEN-3694, ZEN 3694, ZEN-3694, ZEN003694, Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cetuximab, C 225, C-225, C225, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, Encorafenib, Braftovi, LGX 818, LGX-818, LGX818, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning
National Cancer Institute (NCI)
Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
01/27
01/27
C4901001, NCT05538130: A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors

Recruiting
1
124
Canada, US, RoW
PF-07799544, ARRY-134, PF-07799933, ARRY-440, encorafenib, BRAFTOVI
Pfizer
Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Colorectal Cancer
10/27
04/29
NCT04741997: Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Recruiting
1
50
US
Encorafenib Pill, Binimetinib Pill, Nivolumab
H. Lee Moffitt Cancer Center and Research Institute, Pfizer
Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
07/25
07/26
NCT05985954: Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

Recruiting
1
27
US
Cetuximab, ERBITUX, Ulixertinib, BVD-523, Encorafenib
M.D. Anderson Cancer Center, BioMed Valley Discoveries, Inc, Eli Lilly and Company
Metastatic Colorectal Cancer
03/28
03/28
ZN-c3-016, NCT05743036: ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

Hourglass Jul 2024 - Dec 2024 : Initial data for BRAFm mCRC
Hourglass Jan 2023 - Mar 2023 : Initiation of P1/2 dose escalation study of ZN-c3 in combination with encorafenib & cetuximab in patients with BRAF V600E-mutated metastatic CRC
Active, not recruiting
1
44
Europe, US, RoW
ZN-c3, Encorafenib, BRAFTOVI®, Cetuximab, ERBITUX®
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc, Pfizer
Metastatic Colorectal Cancer
07/24
09/26
NCT04903119: Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

Recruiting
1
30
US
Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg, Nilotinib 400mg, Dabrafenib, Trametinib, Encorafenib, Binimetinib
Ruta Arays, Novartis, National Cancer Institute (NCI)
Metastatic Melanoma, BRAF Gene Mutation
07/27
06/29
NCT05806268: Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients

Completed
N/A
214
US
Novartis Pharmaceuticals
BRAF v600 Mutated Metastatic Melanoma
03/22
03/22
NCT05848219: Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib

Terminated
N/A
543
US
Novartis Pharmaceuticals
Metastatic Melanoma
04/22
04/22
TAILOR, NCT04801966: Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

Terminated
N/A
3
RoW
Trametinib, Cobimetinib, Binimetinib, Alpelisib, Vemurafenib, Dabrafenib, Encorafenib, Palbociclib, Olaparib, Ribociclib, Abemaciclib, Talazoparib, Nivolumab, Atezolizumab, Pembrolizumab
Peter MacCallum Cancer Centre, Australia
Cancer
12/22
12/22
NCT05954546: A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings

Completed
N/A
275
US
Enco+bini
Pfizer
Metastatic Melanoma
12/23
12/23
OCEANMIST, NCT05260684: Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US

Completed
N/A
716
US
Encorafenib, Administration route: Oral, Binimetinib, Vemurafenib, Cobimetinib, Dabrafenib, Trametinib
Pfizer
Melanoma
12/23
12/23
SPEBINI, NCT06774989: Real-life Pharmacological Monitoring of Encorafenib-Binimetinib in the Treatment of Metastatic Melanoma

Recruiting
N/A
66
Europe
Assistance Publique - Hôpitaux de Paris
Melanoma (Skin)
01/28
01/28
jRCT2011210010: 38-501 : BRAFTOVI/MEKTOVI Combination Therapy Specified Drug Use Survey (ML)

Completed
N/A
150
Japan
Ono Pharmaceutical Co.,LTD
radically unresectable malignant melanoma with a BRAF gene mutation
 
 
UK-EnBiRiM, NCT07022457: UK ENcorafenib and BInimetinib Real-world Study in Melanoma

Not yet recruiting
N/A
50
Europe
Encorafenib + Binimetinib
Vitaccess Ltd, Pierre Fabre Limited
Metastatic Melanoma, BRAF V600 Mutation Positive
12/27
12/27
BERING CRC, NCT04673955: BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment

Recruiting
N/A
500
Europe
Encorafenib, Braftovi, Cetuximab, Erbitux
Pierre Fabre Pharma GmbH, iOMEDICO AG, Pierre Fabre Pharma AG, Pierre Fabre Pharma Austria
Metastatic Colorectal Carcinoma
09/26
01/27
BERINGMELANOMA, NCT04045691: Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment

Recruiting
N/A
750
Europe
Encorafenib, Binimetinib
Pierre Fabre Pharma GmbH, Pierre Fabre Pharma Austria, Pierre Fabre Pharma AG
Melanoma Stage IV, Melanoma Stage III
12/26
09/27
Nerlynx (neratinib) / Puma
ChiCTR2500097583: A multi-center retrospective study of neratinib as extended adjuvant therapy to describe patient characteristics, treatment patterns, safety, and effectiveness in HER2-positive early breast cancer patients in China

Recruiting
4
500
 
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Pierre Fabre (Shanghai) Medical Co.,Ltd., Pierre Fabre (Shanghai) Medical Co.,Ltd.
Breast Cancer
 
 
NCT05760612: A Clinical Study on Hormone Receptor Positive HER2 Positive Breast Cancer of RCB1-2 After Neoadjuvant Treatment with Trastuzumab Combined with Parezumab

Recruiting
3
300
RoW
Trastuzumab and nelatinib, Trastuzumab and Parstuzumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab, RCB Classification 1-2, Neratini
02/28
11/28
plasmaMATCH, NCT03182634: The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices () Trial

Checkmark Results from cohort B of plasmaMATCH trial in combination with fulvestrant for advanced breast cancer at SABCS 2019
Dec 2019 - Dec 2019: Results from cohort B of plasmaMATCH trial in combination with fulvestrant for advanced breast cancer at SABCS 2019
Recruiting
2a
1150
Europe
Fulvestrant, Neratinib, AZD5363, Olaparib, AZD6738
Institute of Cancer Research, United Kingdom, Royal Marsden NHS Foundation Trust
Advanced Breast Cancer
11/22
11/23
2005-003098-26: Phase 2 Study of HKI-272 in Subjects with Advanced Breast Cancer

Ongoing
2
45
Europe
HKI-272,
Wyeth Research Division of Wyeth Pharmaceuticals Inc.
Breast cancer is the most frequently diagnosed malignancy and the second most common cause of cancer related deaths in women. HER2 is a member of the epidermal growth factor receptor (EGFR) family that includes EGFR/HER1, HER2, HER3 and HER4, all being receptor tyrosine-protein kinases. The oncogenic role of HER2 has been extensively documented in breast cancer, where it is overexpressed in 25% to 30% of breast cancers.
 
 
2013-004391-35: A study before surgery evaluating Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer. Studio clinico precedente all\'intervento chirurgico per valutare i regimi di Paclitaxel settimanale più Neratinib o Trastuzumab o Neratinib e Trastuzumab seguito da Doxorubicina e Ciclofosfamide con Trastuzumab postoperatorio in donne con tumore alla mammella HER2-positivo localmente avanzato.

Ongoing
2
33
Europe
Neratinib, PB-272; HKI-272, Herceptin, Herceptin
Puma Biotechnology Inc., Puma Biotechnology, Inc
Locally advanced HER2-positive breast cancer tumore alla mammella HER2-positivo localmente avanzato
 
 
2019-001896-35: A Clinical Study to Investigate Colon Pathology in Patients With Breast Cancer And HER2 Overexpression When Treated With Neratinib Um estudo clínico para investigar a patologia do cólon em doentes com cancro da mama e sobre-expressão de HER2 quando tratados com Neratinib

Not yet recruiting
2
5
Europe
Neratinib, PB-272; HKI-272, Film-coated tablet
Puma Biotechnology, Inc, Puma Biotechnology, Inc.
HER2 amplified (HER2+) stage 1 through stage 4 primary adenocarcinoma of the breast Adenocarcinoma da mama primário em estadio 1 até ao estadio 4 com amplificação do HER2 (HER2+), Breast Cancer with HER2 gene overexpression Cancro da mama com sobre-expressão do gene HER2, Diseases [C] - Cancer [C04]
 
 
2019-000710-11: Clinical study with Neratinib in Metastatic breast cancer Estudio clínico con Neratinib en cancer de mama metastásico

Not yet recruiting
2
62
Europe
Neratinib, PB-272; HKI-272, Film-coated tablet, Nerlynx
SOLTI, PUMA BIOTECHNOLOGY INC
Pre and post-menopausal women and men with locally advanced or metastatic HR+/HER2-negative endocrine resistant breast cancer Hombres y Mujeres pre y posmenopáusicas con cáncer de mama localmente avanzado o metastásico RH+/HER2-negativo resistente al tratamiento endocrino, Breast cancer Cancer de mama, Diseases [C] - Cancer [C04]
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Braftovi (encorafenib) / Pfizer
2018-003954-26: CYP3A4*22 genotype-guided dosing of TKIs in cancer patients: a new way of personalized therapy Op basis van CYP3A4*22 genotype doseren van tyrosine-kinase remmers bij patiënten met kanker: een nieuwe manier van gepersonaliseerde therapie.

Not yet recruiting
4
198
Europe
Film-coated tablet, Capsule, hard, Coated tablet, Tablet, Cabozantinib/Cabometyx, Cobimetinib/Cotellic, Dabrafenib/Tafinlar, Dasatinib/Sprycel, Erlotinib/Tarceva, Everolimus/Afinitor/Votubia, Imatinib, Lapatinib/Tyverb, Nilotinib/Tasigna, Olaparib/Lynparza, Palbociclib/Ibrance, Ponatinib/Iclusig, Regorafenib/Stivarga, Ruxolitinib/Jakavi, Sunitinib/Sutent, Pazopanib/Votrient, Cabozantinib/Cometriq, Olaparib?Lynparza, Brigatinib - Alunbrig, Encorafenib - Braftovi, Osimertinib/Tagrisso
Erasmus MC Cancer Institute, Erasmus MC
Patients diagnosed with a neoplasm and treated with a tyrosine kinase inhibitor which is mainly metabolised by CYP3A4. Patienten gediagnosticeerd met een maligniteit en behandeld met een tyrosine kinase inhibitor welke voornamelijk wordt gemetaboliseerd door CYP3A4., Patients diagnosed with cancer and treated with a TKI. Patienten gediagnosticeerd met kanker en behandeld met een TKI., Diseases [C] - Cancer [C04]
 
 
NCT05203172 / 2021-004395-34: The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Recruiting
4
46
Europe, Canada, Japan, US, RoW
Binimetinib only treatment, Encorafenib only Treatment, Encorafenib & Binimetinib Treatment, Treatment of Encorafenib & Binimetinib & Ribociclib, Treatment of Encorafenib & Binimetinib & Cetuximab
Pfizer
Solid Tumors
12/26
12/26
COLUMBUS, NCT01909453 / 2013-001176-38: Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

Checkmark 5 year data from COLUMBUS trial in combination with Mektovi in patients with BRAF V600 mutant melanoma
Jul 2022 - Jul 2022: 5 year data from COLUMBUS trial in combination with Mektovi in patients with BRAF V600 mutant melanoma
Checkmark Update on OS data of COLUMBUS trial in combination with Mektovi in patients with BRAF V600 mutant melanoma at ASCO 2019 [screenshot]
May 2019 - Jun 2019: Update on OS data of COLUMBUS trial in combination with Mektovi in patients with BRAF V600 mutant melanoma at ASCO 2019 [screenshot]
Checkmark Approved in combination with Mektovi tablet for unresectable BRAF-mut melanoma
More
Completed
3
921
Europe, Canada, Japan, US, RoW
LGX818, MEK162, vemurafenib, Zelboraf, PLX4032, RO5185426
Pfizer
Melanoma
11/16
09/24
2021-000743-41: Encorafenib used with binimetinib versus placebo in BRAF mutant stage II melanoma after surgery to evaluate the efficacy and safety in preventingmelanoma recurrence Encorafenib utilizzato con binimetinib rispetto al placebo nel melanoma in stadio II con mutazione BRAF dopo l'intervento chirurgico per valutare l'efficacia e la sicurezza nella prevenzione recidiva del melanoma

Not yet recruiting
3
900
Europe
Encorafenib, binimetinib, [W0090], [W0074], Capsule, hard, Film-coated tablet, Braftovi, Mektovi
PIERRE FABRE MéDICAMENT, Pierre Fabre Médicament
Resected BRAF V600E/K stage II melanoma Melanoma asportato BRAF V600E/K stadio II, Stage II melanoma with mutation in the V600E/K gene after surgery Melanoma in stadio II con mutazione nel gene V600E/K dopo intervento chirurgico, Diseases [C] - Cancer [C04]
 
 
2021-004310-19: Encorafenib used with binimetinib versus placebo in BRAF mutant stage IIB/C melanoma after surgery to evaluate the efficacy and safety in preventing melanoma recurrence

Ongoing
3
815
Europe
Encorafenib, binimetinib, W0090, W0074, Capsule, hard, Film-coated tablet, Braftovi, Mektovi
Pierre Fabre Médicament, Pierre Fabre Médicament
Resected BRAF V600E/K stage IIB/C melanoma, Stage IIB/C melanoma with mutation in the V600E/K gene after surgery, Diseases [C] - Cancer [C04]
 
 
BREAKWATER, NCT04607421 / 2020-001288-99: A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Calendar Jan 2025 - Dec 2025: Approval for 1L BRAFV600E metastatic CRC (based on BREAKWATER trial)
Checkmark Data from the safety lead-in portion of BREAKWATER trial in BRAF V600E-mutant mCRC at ASCO-GI 2023
Jan 2023 - Jan 2023: Data from the safety lead-in portion of BREAKWATER trial in BRAF V600E-mutant mCRC at ASCO-GI 2023
Active, not recruiting
3
827
Europe, Canada, Japan, US, RoW
Encorafenib, Braftovi, PF-07263896, LGX818, ONO-7702, Cetuximab, Erbitux, Oxaliplatin, Eloxatin, Irinotecan, Campostar, Leucovorin, Wellcovorin, Fusilev, Khapzory, 5-FU, Fluorouracil, Capecitabine, Xeloda, Bevacizumab, Zirabev
Pfizer, Ono Pharmaceutical Co. Ltd, Merck KGaA, Darmstadt, Germany, Eli Lilly and Company
Neoplasms
12/25
12/26
STARBOARD, NCT04657991 / 2020-004850-31: A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Calendar Jan 2025 - Dec 2025: From STARBOARD trial in combination with Mektovi and Keytruda for for 1L metastatic melanoma
Active, not recruiting
3
256
Europe, Canada, US, RoW
Encorafenib, BRAFTOVI, Binimetinib, MEKTOVI, Pembrolizumab, KEYTRUDA
Pfizer, Merck Sharp & Dohme LLC
Melanoma
09/25
12/25
SU2C ACT3, NCT03803553: Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

Recruiting
3
400
US
FOLFIRI Protocol, FOLinic acid-Fluorouracil-IRInotecan regimen, ACTIVE SURVEILLANCE, Nivolumab Protocol, Nivolumab, Encorafenib/Binimetinib/Cetuximab Protocol, Enco/Bini/Cetux, Trastuzumab + Pertuzumab, Herceptin
Massachusetts General Hospital, Stand Up To Cancer
Metastatic Colon Cancer, Stage III Colon Cancer
12/26
12/27
COLUMBUS-AD, NCT05270044: Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

Active, not recruiting
3
815
Europe, Canada, RoW
Encorafenib and Binimetinib, Encorafenib: Braftovi / Binimetinib: Mektovi, Placebo to match Encorafenib ; Placebo to match Binimetinib
Pierre Fabre Medicament, European Organisation for Research and Treatment of Cancer - EORTC
Melanoma
03/27
05/35
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
A022004, NCT05710406: Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

Active, not recruiting
2/3
1
US
Encorafenib, Braftovi, LGX-818, Cetuximab, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar KL 140, Chimeric Monoclonal Antibody C225, Erbitux, Biospecimen Collection, Computed Tomography, CAT Scan, CT Scan, Magnetic Resonance Imaging, MRI, Patient Observation, Watchful Waiting
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC V8, Stage IIC Colon Cancer AJCC V8, Stage III Colon Cancer AJCC V8
06/34
06/34
BIG BANG, UMIN000031857: A multi-center proof-of-concept phase2 study of encorafenib + binimetinib + cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer

Active, not recruiting
2
36
Japan
Braftovi (encorafenib) - Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) - Ono Pharma, Pierre Fabre, Pfizer, Erbitux (cetuximab) - Eli Lilly, EMD Serono
National Cancer Center Hospital East
Colorectal cancer
 
 
jRCT2011200018: ONO-7702/7703-03:NO-7702/ONO-7703 Phase2 Study

Completed
2
19
Japan
Braftovi (encorafenib) - Pfizer, Mektovi (binimetinib) - Pfizer
Ono Pharmaceutical Co.,LTD
Radically unresectable BRAF V600-mutant thyroid cancer
 
 
ANCHOR-CRC, NCT03693170 / 2018-000271-32: Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer

Hourglass Jan 2021 - Dec 2021 : Pivotal data from trial in combination with Mektovi for 1LBRAF+ mCRC
Checkmark From ANCHOR-CRC trial for BRAF-mutant colorectal Cancer
Jul 2020 - Jul 2020: From ANCHOR-CRC trial for BRAF-mutant colorectal Cancer
Checkmark From ANCHOR-CRC trial in combination with Mektovi for BRAF-mutant colorectal Cancer at ESMO-GI 2020
Jul 2020 - Jul 2020: From ANCHOR-CRC trial in combination with Mektovi for BRAF-mutant colorectal Cancer at ESMO-GI 2020
Completed
2
95
Europe, Japan, US
encorafenib, Braftovi, Binimetinib, Mektovi, Cetuximab, Erbitux
Pierre Fabre Medicament, Pfizer, Merck KGaA, Darmstadt, Germany, Ono Pharmaceutical Co. Ltd
BRAF V600E-mutant Metastatic Colorectal Cancer
06/20
04/23
2020-003283-10: BEACON treatment with cetuximab every second week - cetuximab given every second week with encorafenib in prior treated patients with spred bowel cancer with a specific (BRAF) mutation. A drug trial.

Not yet recruiting
2
53
Europe
Solution for infusion, Capsule, hard, Erbitux, Braftovi
Camilla Qvortrup, Danish Cancer Society, Pirre Fabre
Pre-treated BRAFV600E metastatic colorectal adenocarcinoma., Spred bowel cancer with a specific (BRAF) mutation., Diseases [C] - Cancer [C04]
 
 
2019-004621-24: Encorafenib in combination with Binimetinib in Patients with BRAFV600E-mutant metastatic Lung Cancer

Not yet recruiting
2
105
Europe
Encorafenib, encorafenib, Binimetinib, Docetaxel, W0090, W0074, Capsule, hard, Film-coated tablet, Concentrate for solution for infusion, Braftovi, Mektovi
IFCT, IFCT, Pierre Fabre
BRAFV600E-mutant metastatic Non-small Cell Lung Cancer, Lung Cancer with BRAF V600E mutation, Diseases [C] - Cancer [C04]
 
 
2020-003395-41: Ex vivo drug sensitivity in metastatic colorectal cancer

Not yet recruiting
2
45
Europe
Alectinib, Crizotinib, Dasatinib, Everolimus, Gemcitabine, Idelalisib, Larotrectinib, Methotrexate, Palbociclib, Panobinostat, Pembrolizumab, Pertuzumab, Trastuzumab, Talazoparib, Venetoclax, Cetuximab, Encorafinib, Capsule, hard, Film-coated tablet, Tablet, Infusion, Injection, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Alecensa, Xalkori, Sprycel, Afinitor, Gemcitabine Accord, Zydelig, Vitrakvi, Methotrexat Accord, Ibrance, Farydak, Keytruda, Perjeta, Herceptin, Talzenna, Venclyxto, Erbitux, Braftovi
Oslo University Hospital, Oslo University Hospital
Metastatic Colorectal Cancer, Metastatic Colorectal Cancer, Diseases [C] - Cancer [C04]
 
 
ONO-7702, JapicCTI-205146: Multicenter, open-label, uncontrolled study of and ONO-7703 for metastatic colorectal cancer with BRAF gene mutations (/7703-02E)

Completed
2
Japan
Braftovi (encorafenib) - Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) - Ono Pharma, Pierre Fabre, Pfizer
Ono Pharmaceutical Co., Ltd.
Metastatic colorectal cancer with BRAF gene mutations
 
 
2020-005771-12: Treatment with encorafenib, binimetinib, and cetuximab prior to surgery in patients with BRAF V600E mutated/pMMR localized colorectal cancer

Not yet recruiting
2
48
Europe
Erbitux (cetuximab), Encorafenib, Binimetinib, Solution for infusion, Capsule, hard, , Erbitux (cetuximab), Braftovi (Encorafenib), additional label “intended for clinical trial”
AIO-Studien-gGmbH, Pierre Fabre Pharma GmbH, Merck KGaA
Patients with unresected BRAFV600E mutated/pMMR localized colorectal cancer, Patients with not resected, mutated/mismatch repairable colon cancer, Diseases [C] - Cancer [C04]
 
 
2022-001291-34: A study researching the effectiveness of regorafenib against advanced melanoma where standard therapy has failed.

Not yet recruiting
2
48
Europe
Braftovi, Binimetinib, Trametinib, Dabrafenib, EMEA/H/C/004580, EMEA/H/C/004579, EMEA/H/C/002643, Film-coated tablet, Capsule, Stivarga, Braftovi, Mektovi, Mekinist, Tafinlar
Universitair Ziekenhuis Brussel, Universitair Ziekenhuis Brussel
Advance pretreated melanoma, Patients with advance melanoma that have failed prior systemic treatment with immune checkpoint inhibitors., Diseases [C] - Cancer [C04]
 
 
PHAROS, NCT03915951 / 2019-000417-37: An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Calendar Sep 2020 - Dec 2025: Regulatory approval for BRAF+ metastatic NSCLC in combination with Braftovi
Calendar Sep 2020 - Dec 2025: Regulatory approval for BRAF+ metastatic NSCLC in combination with Mektovi
Hourglass Jul 2019 - Dec 2019 : Initial data from trial for RAS+ MSS CRC
Active, not recruiting
2
98
Europe, US, RoW
encorafenib, binimetinib
Pfizer
Non-small Cell Lung Cancer
09/22
10/25
EBRAIN-MEL, NCT03898908 / 2018-002530-20: Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain

Completed
2
48
Europe
encorafenib, Braftovi, binimetinib, Mektovi, Whole brain radiation therapy, Radiosurgery/stereotactic radiosurgery
Grupo Español Multidisciplinar de Melanoma, Pierre Fabre Medicament, MFAR
Metastatic Melanoma, Brain Metastases
10/22
07/23
2021-000828-35: Pre-surgical treatment evaluating the combination of Encorafenib and Cetuximab for patient with localised colon cancer presenting the BRAF V600E mutation Traitement pré-chirurgical évaluant l'association d'Encorafenib et de Cetuximab pour les patients atteints d'un cancer du côlon localisé présentant la mutation BRAF V600E.

Not yet recruiting
2
30
Europe
Solution for injection, Capsule, Erbitux, braftovi
Fédération Francophone de Cancérologie Digestive, PIERRE FABRE, Merck Serono S.A.S.
Adenocarcinoma of the colon or of the upper rectum (supra-peritoneal) considered operable and histologically confirmed, localised, mutated BRAF V600E, Colon or upper rectum cancer considered operable and presenting a mutation called BRAFV600E, Diseases [C] - Cancer [C04]
 
 
GMMG-BIRMA, NCT02834364: BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)

Completed
2
12
Europe
Encorafenib, LGX818, Binimetinib, MEK162
University of Heidelberg Medical Center, Array BioPharma, German Cancer Research Center, Coordinating Centre for Clinical Trials Heidelberg, University Hospital Heidelberg
Relapsed or Refractory Multiple Myeloma, Patients With BRAFV600 E or BRAFV600K Mutation
03/23
03/23
LOGIC-2, NCT02159066 / 2013-004552-38: LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Checkmark From LOGIC-2 trial for advanced BRAF V600 melanoma at ECC 2015
Sep 2015 - Sep 2015: From LOGIC-2 trial for advanced BRAF V600 melanoma at ECC 2015
Checkmark Clinical activity and tolerability data from LOGIC-2 trial of binimetinib, encorafenib with a third agent (LEE011, BKM120, BFJ398 or INC280) combination for BRAF melanoma at ECC 2015
Sep 2015 - Sep 2015: Clinical activity and tolerability data from LOGIC-2 trial of binimetinib, encorafenib with a third agent (LEE011, BKM120, BFJ398 or INC280) combination for BRAF melanoma at ECC 2015
Completed
2
158
Europe, Canada, US, RoW
LGX818, MEK162, LEE011, BGJ398, BKM120, INC280
Pfizer
Melanoma
01/23
01/23
2021-003640-24: Phase 2 Study of Encorafenib and Binimetinib Plus Pembrolizumab inParticipants With BRAF V600E/K Mutation-Positive Melanoma Who Progressed Duringor After Prior Treatment with Anti−PD-1 Therapy

Ongoing
2
150
Europe
Encorafenib, Binimetinib, Pembrolizumab, Nivolumab, Ipilimumab, PF-07263896, PF-06811462, Capsule, hard, Tablet, Concentrate for solution for infusion, BRAFTOVI®, MEKTOVI®, KEYTRUDA®, OPDIVO, Yervoy
Pfizer Inc., Pfizer Inc., 235 East 42nd Street, New York, NY 10017
metastatic or unresectable locally advanced BRAF V600E/K mutation-positive melanoma, BRAF V600E/K Mutation-Positive Melanoma, Diseases [C] - Cancer [C04]
 
 
2014-004597-42: LGX818 in combination with MEK162 in refractory or relapsed multiple myeloma patients with BRAFV600E or BRAFV600K Mutation

Not yet recruiting
2
15
Europe
encorafenib, binimetinib, LGX818, MEK162, Capsule, hard, Film-coated tablet, Mektovi
Universität Heidelberg vertreten durch die kaufmännische Direktorin, Array BioPharma
Relapsed or refractory Multiple Myeloma, Relapsed or refractory Multiple Myeloma, Diseases [C] - Cancer [C04]
 
 
PREMIUM, NCT05097378: Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma

Not yet recruiting
2
45
Europe
Encorafenib + Binimetinib, Braftovi + Mektovi, Standard Adjuvant Treatment
CCTU- Cancer Theme, Pierre Fabre Medicament
Melanoma, Cancer
09/23
01/24
EBIN, NCT03235245 / 2017-002887-42: Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

Active, not recruiting
2
271
Europe
Nivolumab + Ipilimumab, Encorafenib + Binimetinib
European Organisation for Research and Treatment of Cancer - EORTC
Unresectable Stage III Melanoma, Stage IV Melanoma
10/23
01/27
NCT04390243: Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

Terminated
2
6
US
Binimetinib, ARRY-162, ARRY-438162, MEK162, Mektovi, Encorafenib, Braftovi, LGX 818, LGX-818, LGX818
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
11/23
11/23
ENCO-BRAF, NCT04526782 / 2019-004621-24: ENCOrafenib With Binimetinib in bRAF NSCLC

Hourglass Jul 2022 - Dec 2022 : Pivotal data readout from ENCO-BRAF trial in combination with Mektovi for NSCLC
Active, not recruiting
2
119
Europe
Encorafenib 75 MG, Binimetinib 15 MG
Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre
Non Small Cell Lung Cancer, BRAF V600E
06/25
03/26
BEAVER, NCT03839342: Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations

Active, not recruiting
2
26
Canada
Binimetinib, Encorafenib
University Health Network, Toronto
Solid Tumor
12/25
12/25
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

Completed
2
107
RoW
Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan
Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany
BRAF V600E, Metastatic Colorectal Cancer
12/23
12/24
CEBBRA, NCT06207656: Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer

Recruiting
2
70
Europe
EBC
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Merck, S.L., Spain, Pierre Fabre Ibérica, S.A.
Colorectal Cancer
04/29
04/29
NCT04324112: Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

Recruiting
2
45
US
binimetinib, Encorafenib
National Cancer Institute (NCI)
Hairy Cell Leukemia
04/28
07/28
BRAVE, NCT06411600: Combination Therapy for BRAF-V600E Metastatic CRCm

Recruiting
2
94
Europe
Encorafenib, Cetuximab, Bevacizumab
Vall d'Hebron Institute of Oncology
Metastatic Colorectal Cancer
05/27
05/29
SECOMBIT, NCT02631447 / 2014-004842-92: Sequential Combo Immuno and Target Therapy () Study

Completed
2
251
Europe
LGX818, Combo target, IMP3, MEK162, IMP4, Nivolumab, Combo Immuno, IMP1, Ipilimumab, IMP2
Fondazione Melanoma Onlus, Clinical Research Technology S.r.l.
Metastatic Melanoma
05/24
05/24
MEMBRAINS, NCT03563729 / 2018-000875-34: Melanoma Metastasized to the Brain and Steroids

Recruiting
2
80
Europe
Pembrolizumab Injection [Keytruda], Ipilimumab Injection [Yervoy], Nivolumab Injection [Opdivo], Encorafenib, Binimetinib, Dabrafenib, Trametinib
Inge Marie Svane
Malignant Melanoma
06/24
06/28
ECLYPse, NCT06640166: Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.

Recruiting
2
25
Europe
encorafenib + cetuximab + FOLFIRI, encorafenib, cetuximab, FOLFIRI
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Pierre Fabre Pharma GmbH
Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumor, Colorectal Adenocarcinoma, Colorectal Cancer (CRC), Colorectal Cancer, Colon Cancer, Colon Adenocarcinoma, Colon Carcinoma, Colon Neoplasm
12/25
06/26
NCT05576896: Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

Recruiting
2
43
US
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
Northwestern University, National Cancer Institute (NCI)
Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV
07/24
07/25
BRICKET, NCT06578559: Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC

Recruiting
2
16
Europe
Cetuximab, Encorafenib
Gruppo Oncologico del Nord-Ovest, Merck Sharp & Dohme LLC, Pierre Fabre Laboratories
Colorectal Cancer
08/26
04/27
NeoBRAF, NCT05510895 / 2020-005771-12: Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer

Recruiting
2
48
Europe
Binimetinib, Encorafenib, Cetuximab
AIO-Studien-gGmbH, Pierre Fabre Pharma GmbH, Merck Serono GmbH, Germany, Universitätsklinikum Hamburg-Eppendorf
Colorectal Cancer, Colon Cancer, BRAF V600E, BRAF V600 Mutation, Localized Cancer
07/24
01/25
NEORAF, NCT05706779: Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer

Recruiting
2
30
Europe
Encorafenib Oral Capsule + Cetuximab
Federation Francophone de Cancerologie Digestive, Pierre Fabre Laboratories, Merck Sharp & Dohme LLC
Colorectal Cancer, BRAF V600E Mutation Positive
08/24
08/27
S2107, NCT05308446: Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

Active, not recruiting
2
84
US
Cetuximab, C 225, C-225, C225, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Encorafenib, Braftovi, LGX 818, LGX-818, LGX818, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
02/26
02/26
CA209-73R, NCT04061980: Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

Active, not recruiting
2
24
US
Binimetinib, ARRY-162, ARRY-438162, MEK162, Mektovi, Encorafenib, Braftovi, LGX 818, LGX-818, LGX818, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
Providence Health & Services, Providence Cancer Center, Earle A. Chiles Research Institute
BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8
10/25
10/27
TRIDeNT, NCT02910700: Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Active, not recruiting
2
52
US
Binimetinib, Dabrafenib, Encorafenib, Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study, Trametinib
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
12/25
12/25
NEXUS, jRCT2031220025: NEOADJUVANT AND ADJUVANT CHEMOTHERAPY WITH ENCORAFENIB, BINIMETINIB PLUS CETUXIMAB IN PATIENTS WITH SURGICALLY RESECTABLE BRAF V600E MUTANT COLORECTAL METASTASIS ( study)

Recruiting
2
32
Japan
Braftovi (encorafenib) - Pfizer, Mektovi (binimetinib) - Pfizer, Erbitux (cetuximab) - Eli Lilly
National Cancer Center Hospital East
Patients with surgically resectable BRAF V600E mutant colorectal metastasis
 
 
NCT04221438: Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

Terminated
2
3
US
Binimetinib, NSC 788187, ARRY-438162, MEK162, Mektovi, Conventional Surgery, Encorafenib, ONO-7702, LGX818, Fluorothymidine F-18, 18F-FLT, 3'-deoxy-3'- 18F fluorothymidine, FLT
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma
06/24
01/25
BECOME-MB, NCT04074096 / 2021-006331-26: Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis

Active, not recruiting
2
10
Europe
Stereotaxic radiosurgery (SRS), Binimetinib Oral Tablet, Mektovi, Encorafenib Oral Capsule, Braftovi, Pembrolizumab, Keytruda
UNICANCER, European Association of Dermato Oncology, Pierre Fabre Medicament, Merck Sharp & Dohme LLC
Malignant Melanoma, BRAF V600 Mutation, Brain Metastases
04/25
04/29
NCT05026983: Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

Recruiting
2
35
US
Binimetinib, ARRY-162, ARRY-438162, MEK162, Mektovi, Encorafenib, Braftovi, LGX 818, LGX-818, LGX818, Questionnaire Administration
M.D. Anderson Cancer Center
Clinical Stage IV Cutaneous Melanoma AJCC V8, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC V8
05/25
05/25
OCEANII, NCT05195632: Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer

Active, not recruiting
2
63
RoW
Encorafenib, PF-07263896 or W0090 (in Europe), LGX818 (in US), ONO-7702 (in Japan), Binimetinib, W0074 (in Europe), MEK162 (in US), ARRY-438162 (in US), ONO-7703 (in Japan)
Pierre Fabre Medicament
Non-Small Cell Lung Cancer
05/24
09/26
PORTSIDE, NCT05926960 / 2021-003640-24: A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma

Active, not recruiting
2
38
Europe
encorafenib, BRAFTOVI, binimetinib, MEKTOVI, pembrolizumab, KEYTRUDA®, ipilimumab, YERVOY, nivolumab, OPDIVO
Pfizer, Merck Sharp & Dohme LLC
Melanoma
11/25
11/25
ENCEFALO, NCT06887088: Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

Recruiting
2
33
Europe
Encorafenib + Binimetinib, cemiplimab+fianlimab
Grupo Español Multidisciplinar de Melanoma, Regeneron Pharmaceuticals, MFAR, Pierre Fabre Laboratories
Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases
01/28
01/28
BRAF, NCT03973918: Study of Binimetinib With Encorafenib in Adults With Recurrent V600-Mutated HGG

Terminated
2
5
US
Encorafenib, Braftovi, Binimetinib, Mektovi, Research Bloods, Circulating Tumor DNA, Tumor Tissue
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI), Pfizer
High Grade Glioma, BRAF V600E, BRAF V600K, Anaplastic Astrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Gliosarcoma, Glioblastoma
04/22
10/23
NCT05767879: (Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

Recruiting
2
28
Europe
Encorafenib + Binimetinib
Leiden University Medical Center, Pierre Fabre Laboratories
Melanoma Stage III, In-Transit Metastasis of Cutaneous Melanoma
01/26
01/26
SEAMARK, NCT05217446 / 2021-003715-26: A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

Active, not recruiting
2
107
Europe, Canada, US, RoW
Encorafenib, PF-07263896 LGX818 ONO-7702 W0090, Cetuximab, Erbitux, Pembrolizumab, Keytruda®, MK-3475
Pfizer, Merck Sharp & Dohme LLC, Merck KGaA, Darmstadt, Germany, Eli Lilly and Company
Metastatic Colorectal Cancer
03/26
03/27
MK3475-C01, NCT05304546: Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma

Not yet recruiting
2
12
NA
Pembrolizumab, Keytruda, MK3475, Encorafenib, Braftovi, Binimetinib, Mektovi
Dr. Ronnie Shapira
Malignant Melanoma, Metastatic Melanoma, Immunotherapy, BRAF V600E, Malignant Melanoma Stage IV
06/26
06/27
Strata PATH, NCT05097599: StrataPATH™ (Precision Indications for Approved Therapies)

Terminated
2
11
US
lorlatinib, encorafenib + binimetinib, talazoparib, sacituzumab govitecan, axitinib, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, enfortumab vedotin, Padcev
Strata Oncology, Merck Sharp & Dohme LLC, Pfizer, Gilead Sciences
Cancer, Advanced Solid Tumor
06/24
06/24
SWOG S2000, NCT04511013: A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Recruiting
2
112
US
Binimetinib, ARRY-162, ARRY-438162, MEK162, Mektovi, Encorafenib, Braftovi, LGX 818, LGX-818, LGX818, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
SWOG Cancer Research Network, National Cancer Institute (NCI)
Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
06/27
06/27
EVIDENT, NCT05725200 / 2020-003395-41: Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Recruiting
2
40
Europe
Alectinib, Cetuximab, Crizotinib, Dasatinib, Everolimus, Encorafenib, Gemcitabine, Idelalisib, Larotrectinib, Methotrexate, Palbociclib, Panobinostat, Pembrolizumab, Petrozumab, Trastuzumab, Talazoparib, Venetoclax
Oslo University Hospital, Oslo University Hospital
Metastatic Colorectal Cancer
12/38
12/40
2019-004819-31: First in human study assessing the safety, immunogenicity and efficacy of the cancer vaccine IN01 as second line of treatment in RAS and BRAF mutated metastatic colorectal cancer patients

Not yet recruiting
1/2
70
Europe
trametinib, encorafenib, IN01, Emulsion and suspension for emulsion for injection, Tablet, Capsule, hard, MEKINIST, BRAFTOVI
IN3BIO, IN3BIO
colorectal cancer at a metastatic stage, eligible for a second line treatment and presenting with a constitutive BRAF or RAS mutation, patients with a colorectal cancer with distant metastasis and laboratory identified BRAF or RAS constitutive tumour mutations eligible to receive a second line treatment, Diseases [C] - Cancer [C04]
 
 
CA209-7Y4, NCT04655157: Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma

Terminated
1/2
2
US
encorafenib, BRAFTOVI®, nivolumab, OPDIVO®, ipilimumab, Yervoy®, binimetinib, Mektovi, ARRY-162
Jason J. Luke, MD, Bristol-Myers Squibb
Melanoma
08/22
09/22
NCT01543698 / 2011-005875-17: A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

Checkmark Of binimetinib and encorafenib combination for BRAF melanoma at ASCO 2015
May 2015 - Jun 2015: Of binimetinib and encorafenib combination for BRAF melanoma at ASCO 2015
Checkmark Of binimetinib and encorafenib combination for BRAF melanoma at ASCO 2015
May 2015 - Jun 2015: Of binimetinib and encorafenib combination for BRAF melanoma at ASCO 2015
Checkmark ASCO 2015
More
Completed
1/2
189
Europe, Canada, US, RoW
LGX818, MEK162, LEE011
Pfizer
Solid Tumors Harboring a BRAF V600 Mutation
03/23
03/23
NCT03843775: A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Completed
1/2
17
US
Binimetinib, MEK162 or ARRY-438162, Encorafenib, LGX818
Memorial Sloan Kettering Cancer Center, Array BioPharma
Advanced BRAF Mutant Cancers
09/23
09/23
CELEBRATE, NCT04720768: Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma

Recruiting
1/2
78
RoW
Binimetinib, Encorafenib, Palbociclib
Peter MacCallum Cancer Centre, Australia
Melanoma, Metastasis
12/24
12/24
DETERMINE, NCT06194929: Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

Recruiting
1/2
33
US
Defactinib, Avutometinib, Encorafenib
University of Utah, Verastem, Inc.
Melanoma
01/28
01/30
LANDSCAPE 1011, NCT04585815 / 2020-002829-28: Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Terminated
1/2
34
Europe, US, RoW
Sasanlimab Prefilled syringe, Encorafenib, Binimetinib, Sasanlimab, Axitinib, SEA-TGT
Pfizer
Carcinoma, Non-Small-Cell Lung
05/23
10/24
HERKULES-3, NCT05039177: A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Active, not recruiting
1/2
102
US
ERAS-007, Encorafenib, Braftovi, Cetuximab, Erbitux, Palbociclib, Ibrance
Erasca, Inc.
Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
08/25
12/25
NCT04017650: Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

Active, not recruiting
1/2
38
US
Cetuximab, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Encorafenib, Braftovi, LGX 818, LGX-818, LGX818, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Progressive Disease, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
06/25
06/25
NCT05957367: A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

Recruiting
1/2
94
US
Inlexisertib, DCC-3116, Ripretinib, QINLOCK, DCC-2618
Deciphera Pharmaceuticals, LLC, Pfizer
GIST
03/27
03/29
Keynote 596, NCT02675946: CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors

Recruiting
1b
72
US, RoW
CGX1321, Pembrolizumab, Keytruda, encorafenib, Braftovi, cetuximab, Erbitux
Curegenix Inc., Merck Sharp & Dohme LLC
Solid Tumors, GI Cancer
03/23
03/23
NCT01436656: A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
1
107
Europe, Japan, US, RoW
LGX818
Pfizer
Melanoma and Metastatic Colorectal Cancer
10/12
11/22
2018-001946-32: A study of binimetinib and encorafenib in patients aged 12 to 17 with a specific type of melanoma (BRAF V600-mutant melanoma) that cannot be completely removed by surgery or that has spread to other areas in the body.

Not yet recruiting
1
18
RoW, Europe
Binimetinib, Encorafenib, MEK162, LGX818, Film-coated tablet, Capsule, hard, Mektovi 15 mg film-coated tablets, Braftovi 75 mg hard capsules
Array BioPharma Inc., ARRAY BIOPHARMA INC., Array Biopharma Inc.
Unresectable or metastatic BRAF V600-mutant melanoma, Melanoma (a type of cancer), that cannot be completely removed by surgery or that has spread to other areas of the body, Diseases [C] - Cancer [C04]
 
 
NCT03864042: Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Completed
1
56
Europe, Canada, US
losartan, dextromethorphan, caffeine, omeprazole, midazolam, rosuvastatin, bupropion immediate release (IR), encorafenib, binimetinib, modafinil
Pfizer, Pierre Fabre Laboratories
Advanced Solid Tumors, Metastatic Melanoma
07/22
05/23
NCT04759846: Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Withdrawn
1
12
Europe, RoW
Encorafenib + Binimetinib, Braftovi + Mektovi
Pierre Fabre Medicament
BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma, Hepatic Impairment
05/23
05/23
NCT03543969: Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Active, not recruiting
1
14
US
Encorafenib, BRAFTOVI, BRAF/MEK-inhibitor, Binimetinib, MEKTOVI, Nivolumab, Opdivo
H. Lee Moffitt Cancer Center and Research Institute
Melanoma (Skin), Skin Cancer, Skin Melanoma, Skin Carcinoma
12/24
12/28
NCT04800822: PF-07284892 in Participants With Advanced Solid Tumors

Terminated
1
53
US
PF-07284892, ARRY-558, lorlatinib, Lorbrena; PF-06463922, Lorviqua, binimetinib, Mektovi, PF-06811462, MEK162, cetuximab, Erbitux, encorafenib, Braftovi, PF-07263896, LGX818
Pfizer
Solid Tumor
06/24
06/24
NCT06102902: Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

Recruiting
1
30
US
BET Bromodomain Inhibitor ZEN-3694, BETi ZEN-3694, ZEN 3694, ZEN-3694, ZEN003694, Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cetuximab, C 225, C-225, C225, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, Encorafenib, Braftovi, LGX 818, LGX-818, LGX818, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning
National Cancer Institute (NCI)
Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
01/27
01/27
C4901001, NCT05538130: A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors

Recruiting
1
124
Canada, US, RoW
PF-07799544, ARRY-134, PF-07799933, ARRY-440, encorafenib, BRAFTOVI
Pfizer
Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Colorectal Cancer
10/27
04/29
NCT04741997: Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Recruiting
1
50
US
Encorafenib Pill, Binimetinib Pill, Nivolumab
H. Lee Moffitt Cancer Center and Research Institute, Pfizer
Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
07/25
07/26
NCT05985954: Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

Recruiting
1
27
US
Cetuximab, ERBITUX, Ulixertinib, BVD-523, Encorafenib
M.D. Anderson Cancer Center, BioMed Valley Discoveries, Inc, Eli Lilly and Company
Metastatic Colorectal Cancer
03/28
03/28
ZN-c3-016, NCT05743036: ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

Hourglass Jul 2024 - Dec 2024 : Initial data for BRAFm mCRC
Hourglass Jan 2023 - Mar 2023 : Initiation of P1/2 dose escalation study of ZN-c3 in combination with encorafenib & cetuximab in patients with BRAF V600E-mutated metastatic CRC
Active, not recruiting
1
44
Europe, US, RoW
ZN-c3, Encorafenib, BRAFTOVI®, Cetuximab, ERBITUX®
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc, Pfizer
Metastatic Colorectal Cancer
07/24
09/26
NCT04903119: Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

Recruiting
1
30
US
Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg, Nilotinib 400mg, Dabrafenib, Trametinib, Encorafenib, Binimetinib
Ruta Arays, Novartis, National Cancer Institute (NCI)
Metastatic Melanoma, BRAF Gene Mutation
07/27
06/29
NCT05806268: Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients

Completed
N/A
214
US
Novartis Pharmaceuticals
BRAF v600 Mutated Metastatic Melanoma
03/22
03/22
NCT05848219: Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib

Terminated
N/A
543
US
Novartis Pharmaceuticals
Metastatic Melanoma
04/22
04/22
TAILOR, NCT04801966: Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

Terminated
N/A
3
RoW
Trametinib, Cobimetinib, Binimetinib, Alpelisib, Vemurafenib, Dabrafenib, Encorafenib, Palbociclib, Olaparib, Ribociclib, Abemaciclib, Talazoparib, Nivolumab, Atezolizumab, Pembrolizumab
Peter MacCallum Cancer Centre, Australia
Cancer
12/22
12/22
NCT05954546: A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings

Completed
N/A
275
US
Enco+bini
Pfizer
Metastatic Melanoma
12/23
12/23
OCEANMIST, NCT05260684: Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US

Completed
N/A
716
US
Encorafenib, Administration route: Oral, Binimetinib, Vemurafenib, Cobimetinib, Dabrafenib, Trametinib
Pfizer
Melanoma
12/23
12/23
SPEBINI, NCT06774989: Real-life Pharmacological Monitoring of Encorafenib-Binimetinib in the Treatment of Metastatic Melanoma

Recruiting
N/A
66
Europe
Assistance Publique - Hôpitaux de Paris
Melanoma (Skin)
01/28
01/28
jRCT2011210010: 38-501 : BRAFTOVI/MEKTOVI Combination Therapy Specified Drug Use Survey (ML)

Completed
N/A
150
Japan
Ono Pharmaceutical Co.,LTD
radically unresectable malignant melanoma with a BRAF gene mutation
 
 
UK-EnBiRiM, NCT07022457: UK ENcorafenib and BInimetinib Real-world Study in Melanoma

Not yet recruiting
N/A
50
Europe
Encorafenib + Binimetinib
Vitaccess Ltd, Pierre Fabre Limited
Metastatic Melanoma, BRAF V600 Mutation Positive
12/27
12/27
BERING CRC, NCT04673955: BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment

Recruiting
N/A
500
Europe
Encorafenib, Braftovi, Cetuximab, Erbitux
Pierre Fabre Pharma GmbH, iOMEDICO AG, Pierre Fabre Pharma AG, Pierre Fabre Pharma Austria
Metastatic Colorectal Carcinoma
09/26
01/27
BERINGMELANOMA, NCT04045691: Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment

Recruiting
N/A
750
Europe
Encorafenib, Binimetinib
Pierre Fabre Pharma GmbH, Pierre Fabre Pharma Austria, Pierre Fabre Pharma AG
Melanoma Stage IV, Melanoma Stage III
12/26
09/27
Nerlynx (neratinib) / Puma
ChiCTR2500097583: A multi-center retrospective study of neratinib as extended adjuvant therapy to describe patient characteristics, treatment patterns, safety, and effectiveness in HER2-positive early breast cancer patients in China

Recruiting
4
500
 
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Pierre Fabre (Shanghai) Medical Co.,Ltd., Pierre Fabre (Shanghai) Medical Co.,Ltd.
Breast Cancer
 
 
NCT05760612: A Clinical Study on Hormone Receptor Positive HER2 Positive Breast Cancer of RCB1-2 After Neoadjuvant Treatment with Trastuzumab Combined with Parezumab

Recruiting
3
300
RoW
Trastuzumab and nelatinib, Trastuzumab and Parstuzumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab, RCB Classification 1-2, Neratini
02/28
11/28
plasmaMATCH, NCT03182634: The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices () Trial

Checkmark Results from cohort B of plasmaMATCH trial in combination with fulvestrant for advanced breast cancer at SABCS 2019
Dec 2019 - Dec 2019: Results from cohort B of plasmaMATCH trial in combination with fulvestrant for advanced breast cancer at SABCS 2019
Recruiting
2a
1150
Europe
Fulvestrant, Neratinib, AZD5363, Olaparib, AZD6738
Institute of Cancer Research, United Kingdom, Royal Marsden NHS Foundation Trust
Advanced Breast Cancer
11/22
11/23
2005-003098-26: Phase 2 Study of HKI-272 in Subjects with Advanced Breast Cancer

Ongoing
2
45
Europe
HKI-272,
Wyeth Research Division of Wyeth Pharmaceuticals Inc.
Breast cancer is the most frequently diagnosed malignancy and the second most common cause of cancer related deaths in women. HER2 is a member of the epidermal growth factor receptor (EGFR) family that includes EGFR/HER1, HER2, HER3 and HER4, all being receptor tyrosine-protein kinases. The oncogenic role of HER2 has been extensively documented in breast cancer, where it is overexpressed in 25% to 30% of breast cancers.
 
 
2013-004391-35: A study before surgery evaluating Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer. Studio clinico precedente all\'intervento chirurgico per valutare i regimi di Paclitaxel settimanale più Neratinib o Trastuzumab o Neratinib e Trastuzumab seguito da Doxorubicina e Ciclofosfamide con Trastuzumab postoperatorio in donne con tumore alla mammella HER2-positivo localmente avanzato.

Ongoing
2
33
Europe
Neratinib, PB-272; HKI-272, Herceptin, Herceptin
Puma Biotechnology Inc., Puma Biotechnology, Inc
Locally advanced HER2-positive breast cancer tumore alla mammella HER2-positivo localmente avanzato
 
 
2019-001896-35: A Clinical Study to Investigate Colon Pathology in Patients With Breast Cancer And HER2 Overexpression When Treated With Neratinib Um estudo clínico para investigar a patologia do cólon em doentes com cancro da mama e sobre-expressão de HER2 quando tratados com Neratinib

Not yet recruiting
2
5
Europe
Neratinib, PB-272; HKI-272, Film-coated tablet
Puma Biotechnology, Inc, Puma Biotechnology, Inc.
HER2 amplified (HER2+) stage 1 through stage 4 primary adenocarcinoma of the breast Adenocarcinoma da mama primário em estadio 1 até ao estadio 4 com amplificação do HER2 (HER2+), Breast Cancer with HER2 gene overexpression Cancro da mama com sobre-expressão do gene HER2, Diseases [C] - Cancer [C04]
 
 
2019-000710-11: Clinical study with Neratinib in Metastatic breast cancer Estudio clínico con Neratinib en cancer de mama metastásico

Not yet recruiting
2
62
Europe
Neratinib, PB-272; HKI-272, Film-coated tablet, Nerlynx
SOLTI, PUMA BIOTECHNOLOGY INC
Pre and post-menopausal women and men with locally advanced or metastatic HR+/HER2-negative endocrine resistant breast cancer Hombres y Mujeres pre y posmenopáusicas con cáncer de mama localmente avanzado o metastásico RH+/HER2-negativo resistente al tratamiento endocrino, Breast cancer Cancer de mama, Diseases [C] - Cancer [C04]
 
 
 

Download Options